NASDAQ:XNCR - Xencor News Headlines

$32.12
+0.81 (+2.59 %)
(As of 06/17/2019 11:43 AM ET)
Today's Range
$31.42
Now: $32.12
$32.12
50-Day Range
$29.86
MA: $32.34
$35.64
52-Week Range
$27.75
Now: $32.12
$48.38
Volume804 shs
Average Volume176,034 shs
Market Capitalization$1.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.3

Headlines

Xencor (NASDAQ XNCR) News Headlines

Source:
DateHeadline
Contrasting Xencor (NASDAQ:XNCR) and Integrated BioPharma (NASDAQ:INBP)Contrasting Xencor (NASDAQ:XNCR) and Integrated BioPharma (NASDAQ:INBP)
www.americanbankingnews.com - June 13 at 4:09 PM
Zacks: Analysts Expect Xencor Inc (NASDAQ:XNCR) Will Announce Quarterly Sales of $7.58 MillionZacks: Analysts Expect Xencor Inc (NASDAQ:XNCR) Will Announce Quarterly Sales of $7.58 Million
www.americanbankingnews.com - June 13 at 3:38 AM
Xencor (NASDAQ:XNCR) Coverage Initiated at MizuhoXencor (NASDAQ:XNCR) Coverage Initiated at Mizuho
www.americanbankingnews.com - June 12 at 6:30 PM
 Brokerages Expect Xencor Inc (NASDAQ:XNCR) to Announce -$0.45 EPS Brokerages Expect Xencor Inc (NASDAQ:XNCR) to Announce -$0.45 EPS
www.americanbankingnews.com - June 11 at 2:20 PM
Xencor Inc (NASDAQ:XNCR) Major Shareholder John S. Stafford III Buys 12,641 SharesXencor Inc (NASDAQ:XNCR) Major Shareholder John S. Stafford III Buys 12,641 Shares
www.americanbankingnews.com - June 10 at 5:16 PM
One Thing To Remember About The Xencor, Inc. (NASDAQ:XNCR) Share Price - Yahoo Finance UKOne Thing To Remember About The Xencor, Inc. (NASDAQ:XNCR) Share Price - Yahoo Finance UK
uk.finance.yahoo.com - June 9 at 9:31 AM
One Thing To Remember About The Xencor, Inc. (NASDAQ:XNCR) Share PriceOne Thing To Remember About The Xencor, Inc. (NASDAQ:XNCR) Share Price
finance.yahoo.com - June 8 at 10:56 AM
Xencor (XNCR) Reports First Patient Dosing in Phase 1 Study of XmAb22841 for Treatment of Patients with Advanced Solid Tumors - StreetInsider.comXencor (XNCR) Reports First Patient Dosing in Phase 1 Study of XmAb22841 for Treatment of Patients with Advanced Solid Tumors - StreetInsider.com
www.streetinsider.com - June 3 at 6:29 PM
Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors - Yahoo FinanceXencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors - Yahoo Finance
finance.yahoo.com - June 3 at 8:45 AM
Xencor Inc (XNCR) Given Average Recommendation of "Buy" by AnalystsXencor Inc (XNCR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 31 at 2:34 AM
Along With FDA Clinical Hold Being Lifted, Xencor Has Other Promising Drugs - Seeking AlphaAlong With FDA Clinical Hold Being Lifted, Xencor Has Other Promising Drugs - Seeking Alpha
seekingalpha.com - May 29 at 6:36 PM
Comparing Aimmune Therapeutics (AIMT) and Xencor (XNCR)Comparing Aimmune Therapeutics (AIMT) and Xencor (XNCR)
www.americanbankingnews.com - May 28 at 12:13 PM
Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development - Business WireXencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development - Business Wire
www.businesswire.com - May 23 at 8:54 AM
Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business DevelopmentXencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development
finance.yahoo.com - May 23 at 8:54 AM
Xencor: 1Q Earnings Snapshot - Yahoo FinanceXencor: 1Q Earnings Snapshot - Yahoo Finance
finance.yahoo.com - May 11 at 5:27 PM
Edited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT - Yahoo FinanceEdited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT - Yahoo Finance
finance.yahoo.com - May 10 at 6:30 PM
Xencor Reports First Quarter 2019 Financial Results - Yahoo FinanceXencor Reports First Quarter 2019 Financial Results - Yahoo Finance
finance.yahoo.com - May 10 at 6:30 PM
Xencor up 5% on Q1 beat - Seeking AlphaXencor up 5% on Q1 beat - Seeking Alpha
seekingalpha.com - May 10 at 6:30 PM
Xencor up 5% on Q1 beat - Xencor, Inc. (NASDAQ:XNCR) - Seeking AlphaXencor up 5% on Q1 beat - Xencor, Inc. (NASDAQ:XNCR) - Seeking Alpha
seekingalpha.com - May 10 at 6:30 PM
Xencor Inc (XNCR) Q1 2019 Earnings Call Transcript - Yahoo FinanceXencor Inc (XNCR) Q1 2019 Earnings Call Transcript - Yahoo Finance
finance.yahoo.com - May 10 at 6:30 PM
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2019 Results - Earnings Call Transcript - Seeking AlphaXencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2019 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 10 at 6:30 PM
Xencor Inc (XNCR) Q1 2019 Earnings Call TranscriptXencor Inc (XNCR) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 10 at 6:30 PM
Edited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMTEdited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT
finance.yahoo.com - May 10 at 6:30 PM
Xencor Reports First Quarter 2019 Financial Results - Business WireXencor Reports First Quarter 2019 Financial Results - Business Wire
www.businesswire.com - May 10 at 8:55 AM
Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors - Business WireXencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors - Business Wire
www.businesswire.com - May 7 at 6:37 PM
Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors - Yahoo FinanceXencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors - Yahoo Finance
finance.yahoo.com - May 6 at 8:52 AM
Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid TumorsXencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors
finance.yahoo.com - May 6 at 8:52 AM
Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019
finance.yahoo.com - May 2 at 7:37 PM
Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount?Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount?
finance.yahoo.com - May 1 at 7:06 PM
Form DEF 14A Xencor Inc For: Jun 26 - StreetInsider.comForm DEF 14A Xencor Inc For: Jun 26 - StreetInsider.com
www.streetinsider.com - May 1 at 8:42 AM
See what the IHS Markit Score report has to say about Xencor Inc. - Yahoo FinanceSee what the IHS Markit Score report has to say about Xencor Inc. - Yahoo Finance
finance.yahoo.com - April 30 at 8:45 AM
Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045 - Yahoo FinanceXencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045 - Yahoo Finance
finance.yahoo.com - April 30 at 8:45 AM
Here’s What Hedge Funds Think About Xencor Inc (XNCR) - Yahoo FinanceHere’s What Hedge Funds Think About Xencor Inc (XNCR) - Yahoo Finance
finance.yahoo.com - April 30 at 8:45 AM
Xencor (XNCR) Reports Partial Clinical Hold Lifted on Phase 1 Study of XmAb14045 - StreetInsider.comXencor (XNCR) Reports Partial Clinical Hold Lifted on Phase 1 Study of XmAb14045 - StreetInsider.com
www.streetinsider.com - April 30 at 8:45 AM
Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody ProgramXencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program
finance.yahoo.com - April 2 at 8:53 PM
Xencor, Inc. (XNCR) Move Was Unfounded, Reit Reduce At Nomura - StreetInsider.comXencor, Inc. (XNCR) Move Was Unfounded, Reit Reduce At Nomura - StreetInsider.com
www.streetinsider.com - March 21 at 7:09 PM
First Week of November 15th Options Trading For Xencor - NasdaqFirst Week of November 15th Options Trading For Xencor - Nasdaq
www.nasdaq.com - March 21 at 7:09 PM
Xencor Inc.Xencor Inc.
www.barrons.com - March 20 at 9:12 PM
Xencor Announces Closing of Research Collaboration and License Agreement with GenentechXencor Announces Closing of Research Collaboration and License Agreement with Genentech
finance.yahoo.com - March 8 at 8:59 AM
Is Xencor, Inc.’s (NASDAQ:XNCR) CEO Paid Enough Relative To Peers?Is Xencor, Inc.’s (NASDAQ:XNCR) CEO Paid Enough Relative To Peers?
finance.yahoo.com - March 1 at 6:34 PM
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q4 2018 Results - Earnings Call Transcript - Seeking AlphaXencor, Inc. (XNCR) CEO Bassil Dahiyat on Q4 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 27 at 6:52 PM
Edited Transcript of XNCR earnings conference call or presentation 25-Feb-19 9:30pm GMTEdited Transcript of XNCR earnings conference call or presentation 25-Feb-19 9:30pm GMT
finance.yahoo.com - February 26 at 6:18 PM
Xencor Inc (XNCR) Q4 2018 Earnings Conference Call TranscriptXencor Inc (XNCR) Q4 2018 Earnings Conference Call Transcript
www.fool.com - February 25 at 10:12 PM
Xencor Q4 revenues off 62%; shares down 1% after hoursXencor Q4 revenues off 62%; shares down 1% after hours
seekingalpha.com - February 25 at 6:41 PM
Xencor Reports Fourth Quarter and Full Year 2018 Financial ResultsXencor Reports Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - February 25 at 6:41 PM
Xencor Becomes OversoldXencor Becomes Oversold
www.nasdaq.com - February 22 at 6:40 PM
FDA suspends enrollment in early-stage study of Xencor bispecific antibody; shares down 7%FDA suspends enrollment in early-stage study of Xencor bispecific antibody; shares down 7%
seekingalpha.com - February 20 at 6:28 PM
Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
finance.yahoo.com - February 20 at 9:01 AM
Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019
finance.yahoo.com - February 19 at 6:37 PM
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with GenentechXencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
finance.yahoo.com - February 5 at 10:57 AM
This page was last updated on 6/17/2019 by MarketBeat.com Staff

Featured Article: Investing in Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel